TrialDrug design, development and therapy

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study.

Vincenzo Spagnuolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.